Triastek Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
37
- Latest Deal Type
-
PE Growth
- Financing Rounds
-
12
Triastek General Information
Description
Developer of 3D-printing pharmaceutical technology designed to revolutionize drug delivery and production. The company offers 3D-printed pharmaceuticals, modified-release formulations, solubility-enhancement platforms, intestine-targeting delivery, gastric retention systems, and oral macromolecule delivery, enabling pharmaceutical companies to precisely control drug release through digital formulation design and continuous manufacturing.
Contact Information
Website
www.triastek.comCorporate Office
- Building 24, MAX Technology Park
- Niumber 99 Lizhe Road, Jiangning District
- Nanjing, Jiangsu 211100
- China
Corporate Office
- Building 24, MAX Technology Park
- Niumber 99 Lizhe Road, Jiangning District
- Nanjing, Jiangsu 211100
- China
Triastek Timeline
Triastek Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Triastek Comparisons
Industry
Financing
Details
Triastek Competitors (3)
One of Triastek’s 3 competitors is Aprecia, a Formerly VC-backed company based in Mason, OH.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aprecia | Formerly VC-backed | Mason, OH | ||||
| DFE Pharma | Private Equity-Backed | Goch, Germany | ||||
| Fabrx | Accelerator/Incubator Backed | London, United Kingdom |
Triastek Patents
Triastek Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026145785-A1 | Delayed-release oral drug dosage form and preparation method therefor | Pending | 06-Jan-2025 | ||
| WO-2026124508-A1 | Additive manufacturing system for continuously producing drug product and method | Pending | 11-Dec-2024 | ||
| WO-2025201521-A1 | Modified-release oral pharmaceutical dosage form and preparation method therefor | Pending | 29-Mar-2024 | ||
| AU-2025236285-A1 | Pharmaceutical dosage form for in vivo retention | Pending | 15-Mar-2024 | ||
| WO-2025190389-A1 | Pharmaceutical dosage form for in vivo retention | Pending | 15-Mar-2024 |
Triastek Signals
Triastek Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Triastek FAQs
-
When was Triastek founded?
Triastek was founded in 2015.
-
Where is Triastek headquartered?
Triastek is headquartered in Nanjing, China.
-
What is the size of Triastek?
Triastek has 37 total employees.
-
What industry is Triastek in?
Triastek’s primary industry is Drug Discovery.
-
Is Triastek a private or public company?
Triastek is a Private company.
-
What is Triastek’s current revenue?
The current revenue for Triastek is .
-
How much funding has Triastek raised over time?
Triastek has raised $102M.
-
Who are Triastek’s investors?
Hangzhou Industry Investment Group, Shanghai Lingang Digital Private Equity Fund Management, Essential Capital (China), Shanghai Guoxin Investment, and Triwise Capital are 5 of 16 investors who have invested in Triastek.
-
Who are Triastek’s competitors?
Aprecia, DFE Pharma, and Fabrx are competitors of Triastek.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process